Serum is not required for ex vivo IFN-γ ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program
暂无分享,去创建一个
C. Gouttefangeas | A. Mander | M. J. P. Welters | C. Ottensmeier | S. H. van der Burg | M. Welters | C. Ottensmeier | C. Britten | S. H. Burg | C. Gouttefangeas | C. M. Britten | A. Mander | L. Low | L. Low | Christian H. Ottensmeier | Cécile Gouttefangeas | Lindsey Low
[1] P. Defechereux,et al. Optimization and Limitations of Use of Cryopreserved Peripheral Blood Mononuclear Cells for Functional and Phenotypic T-Cell Characterization , 2009, Clinical and Vaccine Immunology.
[2] Sylvia Janetzki,et al. "MIATA"-minimal information about T cell assays. , 2009, Immunity.
[3] Sylvia Janetzki,et al. Standardization and validation issues of the ELISPOT assay. , 2005, Methods in molecular biology.
[4] A. Mackensen,et al. The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays , 2007, Cancer Immunology, Immunotherapy.
[5] G. Karthikeyan,et al. Progressive degradation of serum samples limits proteomic biomarker discovery. , 2009, Analytical biochemistry.
[6] R. Powell. Clinical Immunology , 1976, The Lancet.
[7] A. Eggermont,et al. A clinical development paradigm for cancer vaccines and related biologics. , 2007, Journal of immunotherapy.
[8] Ferdousi Chowdhury,et al. Fit for purpose? A case study: validation of immunological endpoint assays for the detection of cellular and humoral responses to anti-tumour DNA fusion vaccines , 2009, Cancer Immunology, Immunotherapy.
[9] H. Dockrell,et al. Immunological Outcomes of New Tuberculosis Vaccine Trials: WHO Panel Recommendations , 2008, PLoS medicine.
[10] Lars Mørkrid,et al. Long‐term stability of serum components in the Janus Serum Bank , 2008, Scandinavian journal of clinical and laboratory investigation.
[11] Sjoerd H van der Burg,et al. Therapeutic vaccines in cancer: moving from immunomonitoring to immunoguiding , 2008, Expert review of vaccines.
[12] Holden T Maecker,et al. Precision and linearity targets for validation of an IFNγ ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides , 2008, BMC Immunology.
[13] K. Silina,et al. ELISPOT assays provide reproducible results among different laboratories for T-cell immune monitoring—even in hands of ELISPOT-inexperienced investigators , 2009, Journal of immunotoxicology.
[14] Guido Ferrari,et al. Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. , 2005, AIDS research and human retroviruses.
[15] M. Caulfield,et al. Establishing Acceptance Criteria for Cell-Mediated-Immunity Assays Using Frozen Peripheral Blood Mononuclear Cells Stored under Optimal and Suboptimal Conditions , 2007, Clinical and Vaccine Immunology.
[16] C. Gouttefangeas,et al. Toward the harmonization of immune monitoring in clinical trials: Quo vadis? , 2007, Cancer Immunology, Immunotherapy.
[17] P. van Endert,et al. Serum-free culture medium and IL-7 costimulation increase the sensitivity of ELISpot detection. , 2008, Journal of immunological methods.
[18] A. Dalgleish,et al. Improving the efficacy of cancer immunotherapy. , 2009, European journal of cancer.
[19] P. Elliott,et al. The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine. , 2008, International journal of epidemiology.
[20] L. Ben-Porat,et al. Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium , 2009, Cancer Immunology, Immunotherapy.
[21] Bjoern Peters,et al. HLA class I supertypes: a revised and updated classification , 2008, BMC Immunology.
[22] Sylvia Janetzki,et al. Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI) , 2007, Cancer Immunology, Immunotherapy.
[23] Yingdong Zhao,et al. A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers" , 2008, Journal of Translational Medicine.
[24] S. H. van der Burg,et al. Performance of serum-supplemented and serum-free media in IFNγ Elispot Assays for human T cells , 2009, Cancer Immunology, Immunotherapy.
[25] L. J. Old,et al. Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond , 2010, Cancer Immunology, Immunotherapy.
[26] J. Bartůňková,et al. Department of Immunology , 2009 .